A biotech company has just received regulatory approval to test an experimental oral medication for Ebola in the Democratic Republic of Congo, where the largest Ebola outbreak on record is spreading rapidly and killing at unprecedented rates. As of August 6, 2026, the outbreak caused by Bundibugyo ebolavirus had resulted in 4,141 confirmed cases and 1,889 confirmed deaths, with a fatality rate of 46%. NanoViricides received approval from ACOREP, the local regulatory agency in the Democratic Republic of Congo, to begin Phase II clinical trials of NV-387 Oral Gummies, marking a significant shift in how researchers are approaching treatment for this deadly virus.

Why Is This Outbreak Spreading So Rapidly?

The current Ebola outbreak in the Democratic Republic of Congo is spreading at an unprecedented pace. During the most recent complete reporting week, health officials recorded 567 new cases and 296 deaths, the highest weekly numbers since the outbreak began. What makes this outbreak particularly alarming is that over 80% of new cases have no known contact with infected individuals, suggesting the true scale of the outbreak is at least twice as large as confirmed cases indicate.

The virus has now spread to at least five provinces across the country and has reached displacement camps housing over 4.4 million people displaced by internal conflict. These camps lack adequate drinking water, sanitation, and medical resources, creating ideal conditions for the virus to spread further. The outbreak is being described as spreading "like a wildfire".

What Makes an Oral Treatment Advantageous in This Crisis?

The key advantage of NV-387 is that it's an oral medication, meaning patients can take it by mouth rather than requiring intravenous infusions. This distinction is crucial in a resource-limited setting like the Democratic Republic of Congo. Other treatments currently being tested, such as Remdesivir and antibody cocktails, require infusions that are difficult to administer and cannot be scaled up quickly during a massive outbreak. An oral medication can be distributed more easily and doesn't require specialized medical equipment or trained personnel to administer.

"We believe NV-387 could be revolutionary in this fight against Ebola, if it is found to be effective. It is an oral drug, in contrast to others that are infusions. Thus evaluating if NV-387 treatment works is of paramount importance to combat this and future Ebola and Marburg outbreaks," said Anil R. Diwan.

Anil R. Diwan, President, NanoViricides

According to NanoViricides, the drug works by mimicking features on host cells that the virus requires to infect people. The company claims that because the virus continues to need these cellular features even as it mutates, it's unlikely the virus can develop resistance to the medication. However, it is important to note that NV-387 is an experimental drug that has not yet been proven effective in human trials for Ebola treatment. Results from this Phase II trial are needed to determine if the treatment actually works.

How Does This Approach Compare to Other Treatments Being Tested?

Multiple treatment approaches are currently being tested in the Democratic Republic of Congo. A large collaborative trial called the "PARTNERS" clinical trial is evaluating Remdesivir infusion, an antibody cocktail called MBP134, and combinations of these treatments. However, this trial is expected to require over 1,000 patients and may not yield results for more than a year.

The challenge with antibody-based treatments is that they are highly specific to particular strains of the virus and often lose effectiveness against variants that emerge in the field. The current outbreak is caused by a new variant of Bundibugyo ebolavirus that appears to have recently jumped from animals, likely fruit bats, to humans. Existing antibody treatments designed for other Ebola strains may not work effectively against this new variant without further testing.

How Does NV-387 Differ From Other Experimental Treatments?

• Administration Method: NV-387 is delivered as oral gummies that can be taken by mouth without requiring medical equipment, trained personnel, or intravenous infusions, making it more scalable in resource-limited settings.
• Broad-Spectrum Design: According to NanoViricides, the drug is designed to target multiple Ebola viruses by mimicking host cell features they all require, rather than being specific to a single strain.
• Viral Resistance: The company claims that because the medication targets cellular features the virus must continue using even as it mutates, viral escape is considered highly unlikely, though this has not been proven in human trials.
• Trial Timeline: The Phase II trial is designed to yield results quickly and decisively, rather than requiring the 1,000 or more patients needed for the PARTNERS trial.

A vaccine designed specifically for the Bundibugyo strain has also begun clinical trials in the Democratic Republic of Congo, and authorities are considering whether to test Ervebo, a vaccine approved for a different Ebola strain, despite concerns about its effectiveness against this new variant.

What Is the Current Status of the Clinical Trial?

NanoViricides has partnered with Om Sai Clinical Research, an organization based in India, to conduct the Phase II trial. The trial team includes a principal investigator and other experts working with a university in the Ebola-affected region. Sufficient quantities of NV-387 Oral Gummies have already been shipped to the Democratic Republic of Congo and are ready to begin the trial.

The same research organization is also leading a Phase II trial of NV-387 for treating mpox in the Democratic Republic of Congo, demonstrating the company's broader effort to develop oral antiviral treatments for multiple infectious diseases. The trial preparations have been underway in anticipation of regulatory approval, with the goal of accelerating the timeline to the first patient dosing.

With the outbreak continuing to expand and mortality rates remaining high, the approval of this clinical trial represents a potential new tool in the fight against one of the world's deadliest viruses. However, readers should understand that NV-387 is an experimental medication with no proven efficacy in humans for Ebola treatment. The results from this Phase II trial will be critical in determining whether this oral approach can help contain the outbreak and save lives in the coming months.